Study to Assess the Safety and Tolerability of IV Tonapofylline in Subjects With Acute Decompensated Heart Failure (ADHF) and Renal Insufficiency

NCT ID: NCT00709865

Last Updated: 2023-09-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

420 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-07-31

Study Completion Date

2009-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the current study is to assess the safety and tolerability of intravenous tonapofylline.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Renal Insufficiency Congestive Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

.03 mg/kg

Group Type EXPERIMENTAL

tonapofylline

Intervention Type DRUG

IV

2

.15 mg/kg

Group Type EXPERIMENTAL

tonapofylline

Intervention Type DRUG

IV

3

.3 mg/kg

Group Type EXPERIMENTAL

tonapofylline

Intervention Type DRUG

IV

4

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

IV

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

tonapofylline

IV

Intervention Type DRUG

Placebo

IV

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Adentri BG9928

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Previous diagnosis of heart failure.
* Must have ADHF, requiring hospitalization, with clinical evidence for volume overload

Exclusion Criteria

* History of an allergic reaction to any xanthine-containing substance.
* History of seizure
* History of stroke
* Myocardial infarction
* Uncorrected hemodynamically significant primary valvular disease or known Obstructive or restrictive cardiomyopathy.
* Serious systemic infection
* Major surgical procedures within 30 days
* Acute coronary syndrome
* Cardiogenic shock
* Baseline body weight \>150 kg
* Participation in any other investigational study of drugs or devices within 30 days prior to Screening
* Nursing mothers, pregnant women, or women planning on becoming pregnant during the study
* Presence of any clinically significant condition that might interfere with optimal safe participation in this study
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Biogen

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Medical Director

Role: STUDY_DIRECTOR

Biogen

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Saint Petersburg, , Russia

Site Status

Saint Petersburg, , Russia

Site Status

Saratov, , Russia

Site Status

Tomsk, , Russia

Site Status

Gothenburg, , Sweden

Site Status

Lidköping, , Sweden

Site Status

Huntsville, Alabama, United States

Site Status

Mobile, Alabama, United States

Site Status

Fort Smith, Arkansas, United States

Site Status

Beverly Hills, California, United States

Site Status

Chula Vista, California, United States

Site Status

Mission Viejo, California, United States

Site Status

Monterey Park, California, United States

Site Status

Oceanside, California, United States

Site Status

Redondo Beach, California, United States

Site Status

San Diego, California, United States

Site Status

Sylmar, California, United States

Site Status

Torrance, California, United States

Site Status

Yuba City, California, United States

Site Status

Hartford, Connecticut, United States

Site Status

Jacksonville, Florida, United States

Site Status

Sarasota, Florida, United States

Site Status

Tampa, Florida, United States

Site Status

Lombard, Illinois, United States

Site Status

Indianapolis, Indiana, United States

Site Status

Muncie, Indiana, United States

Site Status

Iowa City, Iowa, United States

Site Status

Kansas City, Kansas, United States

Site Status

Wichita, Kansas, United States

Site Status

Baltimore, Maryland, United States

Site Status

Ayer, Massachusetts, United States

Site Status

Boston, Massachusetts, United States

Site Status

Hyannis, Massachusetts, United States

Site Status

Springfield, Massachusetts, United States

Site Status

West Springfield, Massachusetts, United States

Site Status

Traverse City, Michigan, United States

Site Status

Minneapolis, Minnesota, United States

Site Status

Kansas City, Missouri, United States

Site Status

Lee's Summit, Missouri, United States

Site Status

St Louis, Missouri, United States

Site Status

Omaha, Nebraska, United States

Site Status

Ridgewood, New Jersey, United States

Site Status

Johnson City, New York, United States

Site Status

Mineola, New York, United States

Site Status

New York, New York, United States

Site Status

Stony Brook, New York, United States

Site Status

The Bronx, New York, United States

Site Status

Concord, North Carolina, United States

Site Status

Cincinnati, Ohio, United States

Site Status

Cleveland, Ohio, United States

Site Status

Columbus, Ohio, United States

Site Status

Franklin, Ohio, United States

Site Status

Oklahoma City, Oklahoma, United States

Site Status

Oklahoma City, Oklahoma, United States

Site Status

Tulsa, Oklahoma, United States

Site Status

Portland, Oregon, United States

Site Status

Camp Hill, Pennsylvania, United States

Site Status

Danville, Pennsylvania, United States

Site Status

Doylestown, Pennsylvania, United States

Site Status

Lancaster, Pennsylvania, United States

Site Status

Philadelphia, Pennsylvania, United States

Site Status

Providence, Rhode Island, United States

Site Status

Orangeburg, South Carolina, United States

Site Status

Nashville, Tennessee, United States

Site Status

Oak Ridge, Tennessee, United States

Site Status

Tullahoma, Tennessee, United States

Site Status

Dallas, Texas, United States

Site Status

Houston, Texas, United States

Site Status

San Antonio, Texas, United States

Site Status

Whitney, Texas, United States

Site Status

Danville, Virginia, United States

Site Status

Olympia, Washington, United States

Site Status

Tacoma, Washington, United States

Site Status

Charleston, West Virginia, United States

Site Status

Buenos Aires, BUE, Argentina

Site Status

Buenos Aires, BUE, Argentina

Site Status

Capital Federal, CBA, Argentina

Site Status

Corrientes, COR, Argentina

Site Status

Córdoba, CRD, Argentina

Site Status

Villa Cabrera, CRD, Argentina

Site Status

Santa Fe, SFE, Argentina

Site Status

Santa Fe, SFE, Argentina

Site Status

San Luis, SLS, Argentina

Site Status

San Miguel de Tucumán, TUC, Argentina

Site Status

Capital Federal, , Argentina

Site Status

Darlinghurst, New South Wales, Australia

Site Status

Liverpool, New South Wales, Australia

Site Status

Canberra, , Australia

Site Status

Dandenong, , Australia

Site Status

Melbourne, , Australia

Site Status

Fortaleza, Ceará, Brazil

Site Status

Porto Alegre, Rio Grande do Sul, Brazil

Site Status

Aracaju, Sergipe, Brazil

Site Status

Santo André, São Paulo, Brazil

Site Status

São José do Rio Preto, São Paulo, Brazil

Site Status

Campo Grande, , Brazil

Site Status

Curitiba, , Brazil

Site Status

Porto Alegre, , Brazil

Site Status

Porto Alegre, , Brazil

Site Status

Recife, , Brazil

Site Status

Pazardzhik, , Bulgaria

Site Status

Pleven, , Bulgaria

Site Status

Sofia, , Bulgaria

Site Status

Sofia, , Bulgaria

Site Status

Sofia, , Bulgaria

Site Status

Sofia, , Bulgaria

Site Status

Vancouver, British Columbia, Canada

Site Status

Saint John, New Brunswick, Canada

Site Status

Kolín, , Czechia

Site Status

Uherské Hradiště, , Czechia

Site Status

Hus, , Finland

Site Status

Lahti, , Finland

Site Status

Oulu, , Finland

Site Status

Seinäjoki, , Finland

Site Status

Turku, , Finland

Site Status

Albi, , France

Site Status

Antony, , France

Site Status

Caen, , France

Site Status

Cholet, , France

Site Status

Paris, , France

Site Status

Poitiers, , France

Site Status

Pontoise, , France

Site Status

Strasbourg, , France

Site Status

Toulouse, , France

Site Status

Tourcoinq, , France

Site Status

Frankfurt am Main, Hesse, Germany

Site Status

Bad Nauheim, , Germany

Site Status

Berlin, , Germany

Site Status

Berlin, , Germany

Site Status

Bochum, , Germany

Site Status

Essen, , Germany

Site Status

Frankfurt, , Germany

Site Status

Göttingen, , Germany

Site Status

Leipzig, , Germany

Site Status

Regensburg, , Germany

Site Status

Wuppertal, , Germany

Site Status

Bangalore, Karna, India

Site Status

Pune, Mahara, India

Site Status

New Delhi, National Capital Territory of Delhi, India

Site Status

Bangalore, , India

Site Status

Bikaner, , India

Site Status

Chennai, , India

Site Status

Delhi, , India

Site Status

Indore, , India

Site Status

Thrissur, , India

Site Status

Ashkelon, , Israel

Site Status

Beer Yaakov, , Israel

Site Status

Haifa, , Israel

Site Status

Holon, , Israel

Site Status

Jerusalem, , Israel

Site Status

Jerusalem, , Israel

Site Status

Jerusalem, , Israel

Site Status

Kfar Saba, , Israel

Site Status

Nahariya, , Israel

Site Status

Nazareth, , Israel

Site Status

Petah Tikva, , Israel

Site Status

Safed, , Israel

Site Status

Tel Aviv, , Israel

Site Status

Mantova, , Italy

Site Status

Milan, , Italy

Site Status

Pavia, , Italy

Site Status

Maastricht, , Netherlands

Site Status

The Hague, , Netherlands

Site Status

Zwolle, , Netherlands

Site Status

Kościerzyna, , Poland

Site Status

Olsztyn, , Poland

Site Status

Słupsk, , Poland

Site Status

Tarnów, , Poland

Site Status

Warsaw, , Poland

Site Status

Warsaw, , Poland

Site Status

Wroclaw, , Poland

Site Status

Wroclaw, , Poland

Site Status

Bacau, , Romania

Site Status

Bucharest, , Romania

Site Status

Bucharest, , Romania

Site Status

Bucharest, , Romania

Site Status

Barnaul, , Russia

Site Status

Kemerovo, , Russia

Site Status

Krasnoyarsk, , Russia

Site Status

Moscow, , Russia

Site Status

Moscow, , Russia

Site Status

Moscow, , Russia

Site Status

Moscow, , Russia

Site Status

Moscow, , Russia

Site Status

Novosibirsk, , Russia

Site Status

Novosibirsk, , Russia

Site Status

Novosibirsk, , Russia

Site Status

Saint Petersburg, , Russia

Site Status

Saint Petersburg, , Russia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Argentina Australia Brazil Bulgaria Canada Czechia Finland France Germany India Israel Italy Netherlands Poland Romania Russia Sweden

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

160HF301

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.